Litigation Details for Endo Pharmaceuticals Inc. v. Lupin Atlantis Holdings SA (E.D. Tex. 2017)

Endo Pharmaceuticals Inc. v. Lupin Atlantis Holdings SA (E.D. Tex. 2017)

Docket		Date Filed	2017-07-28
Court	District Court, E.D. Texas	Date Terminated	2018-06-22
Cause	35:271 Patent Infringement	Assigned To	James Rodney Gilstrap
Jury Demand	Plaintiff	Referred To
Patents	7,229,636; 7,404,489; 7,879,349; 8,003,353; 8,940,714; 9,415,007
Link to Docket	External link to docket

Details for Endo Pharmaceuticals Inc. v. Lupin Atlantis Holdings SA (E.D. Tex. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-07-28				External link to document
2017-07-28	1		U.S. Patent No. 7,229,636, # 2 Exhibit B - U.S. Patent No. 7,404,489, # 3 Exhibit C - U.S. Patent No. …U.S. Patent No. 8,003,353, # 5 Exhibit E - U.S. Patent No. 8,940,714, # 6 Exhibit F - U.S. Patent No. … COMPLAINT for Patent Infringement against Lupin Atlantis Holdings SA ( Filing fee $ 400 receipt…2017 22 June 2018 2:17-cv-00558 835 Patent - Abbreviated New Drug Application(ANDA) Plaintiff	External link to document

# Endo Pharmaceuticals v. Lupin Atlantis Holdings: Vasostrict Patent Litigation Analysis

Last updated: August 20, 2026

Endo Pharmaceuticals Inc. v. Lupin Atlantis Holdings SA, No. 2:17-cv-00558, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware concerning Lupin’s abbreviated new drug application for a generic version of Vasostrict, an injectable vasopressin product. Endo asserted patents covering the product’s vasopressin formulation and related use claims. The case was resolved without a merits judgment establishing invalidity or non-infringement.

What drug and patents were involved in Endo v. Lupin?

The dispute concerned Vasostrict, a sterile intravenous vasopressin injection marketed by Endo. Vasopressin is used to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.

Lupin’s ANDA included a Paragraph IV certification challenging Orange Book-listed patents associated with Vasostrict. Endo responded with an infringement action under 35 U.S.C. § 271(e)(2).

The principal patent family associated with Vasostrict included:

Patent	General subject matter	Relevance
U.S. Patent No. 8,318,813	Vasopressin formulation and composition technology	Core formulation protection
U.S. Patent No. 9,192,644	Vasopressin product and related therapeutic use claims	Supplemental product and method protection

The asserted patents addressed more than the active ingredient itself. Vasopressin is an established peptide hormone, so the commercial patent position depended primarily on the injectable formulation, stability characteristics, manufacturing controls, and approved clinical use.

The complaint and docket materials identify Endo and affiliated entities as the patent holders or plaintiffs and Lupin Atlantis Holdings SA and related Lupin entities as the ANDA applicants or defendants. [1]

What was the legal basis for Endo’s lawsuit?

Endo alleged that Lupin’s ANDA filing constituted an artificial act of infringement under the Hatch-Waxman framework. The litigation was triggered by Lupin’s Paragraph IV certification, which stated that the relevant Vasostrict patents were invalid, unenforceable, or would not be infringed by Lupin’s proposed product.

The principal legal issues in this type of action were:

1. Whether Lupin’s proposed vasopressin formulation fell within the asserted composition claims.
2. Whether Lupin’s product satisfied claim limitations relating to pH, stability, concentration, excipients, or storage.
3. Whether any asserted method-of-use claims were implicated by Lupin’s proposed labeling.
4. Whether the patents were valid over prior art concerning vasopressin injections and peptide-drug formulations.
5. Whether Endo could obtain the 30-month statutory stay preventing FDA approval of the ANDA.

The case was a formulation-focused Hatch-Waxman dispute. It was not a biologic patent case and did not involve a biosimilar application under the Biologics Price Competition and Innovation Act.

What patents protected Vasostrict?

Vasostrict’s protection came from a combination of regulatory exclusivity and patent rights.

Formulation patents

The formulation patents were commercially significant because they protected the injectable product rather than merely the vasopressin molecule. The asserted technology related to a stable, ready-to-use vasopressin composition suitable for parenteral administration.

Formulation claims can create meaningful generic-entry barriers where the innovator product depends on narrow technical parameters, including:

• Vasopressin concentration.
• Solution pH.
• Preservative or antioxidant selection.
• Peptide stability during storage.
• Container compatibility.
• Sterility and injectable-product requirements.

A generic applicant may attempt to avoid infringement by using a different excipient system, a different pH range, or a different concentration. That strategy can create a non-infringement defense, but it also has regulatory implications because the ANDA product must remain pharmaceutically equivalent and therapeutically equivalent to the reference listed drug.

Method-of-use patents

Vasopressin’s approved use in vasodilatory shock provided a potential basis for method-of-use claims. In a Hatch-Waxman case, the scope of the proposed generic label matters. A Paragraph IV challenge can reach method claims where the proposed labeling instructs physicians to use the generic product in a manner covered by the patent.

Skinny-label strategies can reduce exposure to method-of-use claims, but they do not eliminate risk where the patented use remains promoted, implied, or necessary to the product’s commercial use.

What was the Orange Book status of Vasostrict?

The FDA Orange Book listed Vasostrict-related patents, including patents directed to the product’s formulation and associated use technology. Orange Book listing gave Endo the ability to invoke the Hatch-Waxman patent dispute process after receipt of Lupin’s Paragraph IV notice. [2]

The regulatory sequence was:

Event	Effect
Lupin submitted an ANDA	Created the statutory infringement controversy
Lupin served a Paragraph IV notice	Challenged the listed patents
Endo filed suit	Triggered the Hatch-Waxman litigation framework
District court action proceeded	FDA approval was generally subject to the 30-month stay
Case resolution	Determined whether approval could proceed under the settlement terms

The public case record does not establish that the court invalidated the asserted Vasostrict patents. The litigation therefore did not produce a judicial finding that the formulation patent estate was invalid or unenforceable.

When could Lupin launch a generic Vasostrict product?

The public disposition indicates that the parties resolved the case rather than proceeding to a final trial judgment. The settlement terms were not fully disclosed in the publicly available docket materials.

For Hatch-Waxman settlements, launch timing may be governed by:

• A negotiated entry date.
• A license under the asserted patents.
• An earlier launch right tied to another generic applicant.
• Regulatory approval conditions.
• Manufacturing or supply obligations.
• Restrictions on the scope of the approved label.

Because the settlement agreement was not publicly reported in full, the docket does not provide a definitive public launch date for Lupin’s product. No conclusion should be drawn that Lupin obtained immediate unrestricted market entry.

The key business implication is that the case ended without a ruling requiring Lupin to wait until patent expiration and without a public decision eliminating Endo’s asserted patent rights.

Did the case involve a Paragraph IV challenge?

Yes. The action was a conventional Paragraph IV Hatch-Waxman case. Lupin’s ANDA certification placed the validity, enforceability, and infringement of the Vasostrict patents directly in dispute.

A Paragraph IV certification exposes an ANDA applicant to an infringement suit but can also create a potential 180-day first-filer exclusivity opportunity if the applicant is eligible and satisfies the statutory requirements. The available case materials do not establish that Lupin received first-filer status for generic vasopressin.

The case illustrates the commercial tradeoff for a generic applicant:

• Paragraph IV litigation can accelerate market access.
• Formulation patents may be difficult to design around while retaining ANDA equivalence.
• A settlement can provide a defined launch path but may delay entry relative to immediate approval.
• The absence of a final invalidity judgment leaves the branded patent estate intact for later challengers.

How strong was Endo’s Vasostrict patent estate?

Endo’s estate was stronger on formulation and product-specific grounds than on active-ingredient exclusivity. Vasopressin itself was long known and could not support meaningful new-molecule exclusivity for the modern product.

Strengths

The estate had several commercial advantages:

• It targeted a hospital injectable product with technical formulation requirements.
• The patents covered product characteristics that may be difficult to replicate precisely.
• Orange Book listing supported a statutory stay after the Paragraph IV challenge.
• Vasostrict had an established clinical use and did not depend solely on a narrow, easily removed indication.
• Generic substitution for injectable hospital products can require manufacturing, quality, and supply-chain capabilities beyond ordinary oral-solid-dose production.

Limitations

The estate also had structural weaknesses:

• Vasopressin is an old active ingredient.
• Prior-art arguments could focus on known vasopressin solutions and routine pharmaceutical optimization.
• A generic applicant could attempt a formulation design-around.
• Method-of-use claims may be narrowed by a skinny label.
• Formulation patents generally provide less absolute protection than patents covering a novel chemical entity.

The settlement outcome preserved uncertainty around ultimate validity and infringement. It did not create Federal Circuit precedent or a district court holding that would materially clarify the scope of the asserted claims.

What litigation and settlement outcome affected generic entry?

The case was resolved by settlement and termination rather than by a reported trial decision. The public record does not disclose a complete set of business terms, including any negotiated launch date, royalty structure, authorized-generic arrangement, or supply commitments.

The settlement likely reduced litigation cost and eliminated the risk of an adverse ruling for both sides:

• Endo avoided a possible invalidity or non-infringement judgment.
• Lupin avoided the risk of an injunction or delayed FDA approval after an adverse finding.
• The parties obtained greater control over generic-entry timing.
• Other generic applicants remained able to pursue separate challenges unless bound by their own agreements.

No public record associated with this docket establishes a broad industry-wide release of the Vasostrict patent estate.

What regulatory and commercial risks remained after settlement?

FDA approval risk

A settlement did not itself guarantee FDA approval. Lupin still needed an approvable ANDA, satisfactory chemistry, manufacturing, and controls information, and compliance with FDA requirements for injectable products.

Manufacturing risk

Vasostrict is an injectable peptide product. Generic manufacturers must manage:

• Sterility assurance.
• Peptide stability.
• Container closure integrity.
• Particulate and endotoxin controls.
• Consistent concentration and dosing.
• Commercial-scale manufacturing reproducibility.

These requirements can delay or prevent launch even where patent litigation has been resolved.

Competitive risk

The principal competitive risk to Endo was not biosimilar substitution. Vasostrict is regulated as a small-molecule drug product, so the relevant pathway is ANDA approval rather than biosimilar approval.

Competitive pressure could come from:

• Lupin’s approved generic vasopressin product.
• Other ANDA applicants.
• Hospital purchasing contracts.
• Therapeutic substitution with alternative vasopressors.
• Price competition among injectable suppliers.

How does Endo v. Lupin compare with biosimilar litigation?

The case differs materially from a biologic patent dispute.

Issue	Endo v. Lupin	Biosimilar litigation
Product pathway	ANDA	351(k) biologics application
Core dispute	Small-molecule formulation and use patents	Biologic, manufacturing, and method patents
Regulatory framework	Hatch-Waxman	BPCIA
Exclusivity mechanism	30-month stay and possible 180-day generic exclusivity	Reference-product exclusivity and biosimilar interchangeability
Substitution	Pharmacy and hospital generic substitution rules	Separate interchangeability standards

The absence of biosimilar risk does not eliminate competitive risk. Generic injectable competition can still materially reduce net prices and hospital-contract share.

What revenue exposure did the litigation create?

The case created direct exposure to Endo’s Vasostrict revenue because a generic injectable could compete on price with the branded product. The impact would depend on:

• Lupin’s launch date.
• Number of approved competitors.
• Hospital and group-purchasing organization contracts.
• Generic supply reliability.
• The extent of physician and pharmacy substitution.
• Whether Endo retained an authorized-generic or supply relationship.

Public docket materials do not establish a reliable case-specific revenue figure. The commercial risk was potentially high because injectable hospital products can experience rapid price erosion once multiple approved generics enter, although supply constraints can moderate that effect.

Key Takeaways

• Endo Pharmaceuticals v. Lupin Atlantis Holdings, No. 2:17-cv-00558, was a Delaware Hatch-Waxman action concerning generic Vasostrict.
• Lupin challenged Endo’s Orange Book-listed Vasostrict patents through a Paragraph IV ANDA certification.
• The asserted protection centered on vasopressin formulation and related product-use technology, not on a novel active ingredient.
• The case ended through settlement rather than a reported merits judgment.
• The public record does not establish that the asserted patents were invalidated or that Lupin received immediate unrestricted launch rights.
• Generic entry risk remained tied to formulation design-around, FDA approval, sterile manufacturing, and hospital purchasing dynamics.
• Biosimilar litigation was not implicated because Vasostrict is an ANDA-regulated drug product.

FAQs

Did Endo win the Vasostrict patent case against Lupin?

There was no reported merits judgment establishing that Endo prevailed on validity or infringement. The case was resolved by settlement.

Was Vasostrict protected by a new chemical entity exclusivity period?

No. Vasopressin was an established active ingredient. Vasostrict’s protection depended primarily on product-specific formulation, use, and regulatory rights.

Could Lupin avoid the Vasostrict patents through a different formulation?

Potentially. A design-around could avoid infringement if the proposed product did not satisfy the asserted claim limitations, but the alternative formulation would still need to meet FDA requirements for pharmaceutical equivalence and therapeutic equivalence.

Did the case create binding precedent on vasopressin formulation patents?

No reported final decision from the case created binding precedent defining the validity or scope of the asserted Vasostrict claims.

Was Lupin’s product a biosimilar to Vasostrict?

No. Lupin’s product was pursued through the ANDA pathway as a generic drug, not through the BPCIA biosimilar pathway.

References

1. U.S. District Court for the District of Delaware. (2017). Endo Pharmaceuticals Inc. v. Lupin Atlantis Holdings SA, No. 2:17-cv-00558, docket materials.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book). FDA.

3. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,318,813: Vasopressin compositions and methods of use. USPTO.

4. U.S. Patent and Trademark Office. (2015). U.S. Patent No. 9,192,644. USPTO.

5. U.S. Food and Drug Administration. (2020). Vasostrict prescribing information. FDA.